Figure 4From: Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trialsSignificant Predictors for Progression Free Survival (PFS) at the meta-regression analysis.Back to article page